BR112018012927A2 - reguladores cftr e métodos de uso dos mesmos - Google Patents

reguladores cftr e métodos de uso dos mesmos

Info

Publication number
BR112018012927A2
BR112018012927A2 BR112018012927A BR112018012927A BR112018012927A2 BR 112018012927 A2 BR112018012927 A2 BR 112018012927A2 BR 112018012927 A BR112018012927 A BR 112018012927A BR 112018012927 A BR112018012927 A BR 112018012927A BR 112018012927 A2 BR112018012927 A2 BR 112018012927A2
Authority
BR
Brazil
Prior art keywords
methods
cftr
regulators
cftr regulators
disorders
Prior art date
Application number
BR112018012927A
Other languages
English (en)
Inventor
Verkman Alan
H Levin Marc
Cil Onur
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112018012927A2 publication Critical patent/BR112018012927A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

são fornecidos no presente documento compostos que ativam cftr e métodos para tratar constipação, transtornos de olho seco ou outras doenças e transtornos.
BR112018012927A 2015-12-24 2016-12-23 reguladores cftr e métodos de uso dos mesmos BR112018012927A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24
PCT/US2016/068561 WO2017112947A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112018012927A2 true BR112018012927A2 (pt) 2018-12-11

Family

ID=59091233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012927A BR112018012927A2 (pt) 2015-12-24 2016-12-23 reguladores cftr e métodos de uso dos mesmos

Country Status (17)

Country Link
US (2) US20190031630A1 (pt)
EP (1) EP3394083B9 (pt)
JP (1) JP6894902B2 (pt)
KR (1) KR20180101415A (pt)
CN (1) CN108699107B (pt)
AU (2) AU2016377782B2 (pt)
BR (1) BR112018012927A2 (pt)
CA (1) CA3009531A1 (pt)
CL (1) CL2018001714A1 (pt)
CO (1) CO2018007239A2 (pt)
ES (1) ES2901002T3 (pt)
IL (2) IL299924A (pt)
PL (1) PL3394083T3 (pt)
PT (1) PT3394083T (pt)
RU (1) RU2742934C2 (pt)
WO (1) WO2017112947A1 (pt)
ZA (1) ZA201804228B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
WO2022084741A1 (en) 2020-10-23 2022-04-28 Ildong Pharmaceutical Co., Ltd. Cftr modulator compounds, compositions, and uses thereof
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9815785A (pt) 1998-03-31 2000-12-05 Warner Lambert Co Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina
EA009847B1 (ru) * 2002-09-30 2008-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
EP1716122B1 (en) * 2004-01-30 2017-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7977322B2 (en) * 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
MX2010009576A (es) 2008-03-05 2010-09-24 Merck Patent Gmbh Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
NZ592687A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
TWI450891B (zh) * 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
EP3116501A1 (en) * 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2952862A1 (en) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Also Published As

Publication number Publication date
US20200140402A1 (en) 2020-05-07
IL260210B2 (en) 2023-06-01
RU2018126959A (ru) 2020-01-24
KR20180101415A (ko) 2018-09-12
IL299924A (en) 2023-03-01
AU2021257948B2 (en) 2023-11-30
AU2021257948A1 (en) 2021-11-25
US20190031630A1 (en) 2019-01-31
PT3394083T (pt) 2021-12-07
PL3394083T3 (pl) 2022-01-17
CA3009531A1 (en) 2017-06-29
CL2018001714A1 (es) 2018-10-26
EP3394083B9 (en) 2022-04-27
EP3394083B1 (en) 2021-09-01
CN108699107B (zh) 2022-05-10
EP3394083A4 (en) 2019-09-04
ES2901002T9 (es) 2022-06-20
RU2742934C2 (ru) 2021-02-11
CO2018007239A2 (es) 2018-07-19
IL260210A (en) 2018-07-31
CN108699107A (zh) 2018-10-23
ZA201804228B (en) 2020-09-30
EP3394083A1 (en) 2018-10-31
US11192869B2 (en) 2021-12-07
AU2016377782A1 (en) 2018-07-12
JP6894902B2 (ja) 2021-06-30
AU2016377782B2 (en) 2021-07-29
RU2018126959A3 (pt) 2020-08-20
JP2018538354A (ja) 2018-12-27
ES2901002T3 (es) 2022-03-21
WO2017112947A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
BR112017006664A2 (pt) terapias de combinação
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
BR112018070133A2 (pt) dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201790998A1 (ru) Иммуннорегуляторные агенты
BR112018012927A2 (pt) reguladores cftr e métodos de uso dos mesmos
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]